Printer Friendly

CYTOGEN ANNOUNCES FDA REVIEW UPDATE

 CYTOGEN ANNOUNCES FDA REVIEW UPDATE
 PRINCETON, N.J., July 1 /PRNewswire/ -- Cytogen Corporation


(NASDAQ: CYTO) today announced that the process to seek FDA approval of its lead products, OncoScint(R) colorectal and ovarian, continues and should reach a successful conclusion soon.
 The company had previously communicated its hopes to gain the approval by June.
 Cytogen's President Thomas J. McKearn, commenting on this situation, indicated, "We believe we are in the final stages of this approval process, and we anticipate a favorable outcome. The FDA is now reviewing our medical educational materials and product labeling. There have been no extraordinary requests for new information, nor do we foresee any reason for a protracted delay. Operationally, we are ready to launch the product. Financially, the delay will add somewhat to our interim operating loss, but we are still very confident that our 1992 full-year losses will be substantially less than the $17 million loss we realized in 1991. Our cash balance is sufficient to support higher interim losses without any difficulty."
 Cytogen is a biopharmaceutical company engaged in the development of proprietary systems utilizing monoclonal antibodies for the targeted delivery of diagnostic and therapeutic substances in human health care applications. Cytogen uses its patented and proprietary antibody "linker" technology to develop specific cancer diagnostic imaging and cancer therapeutic products, as well as certain other products.
 /delval/
 -0- 7/1/92
 /CONTACT: Martin D. Cleary, group vice president of Cytogen, 609-987-8221/
 (CYTO) CO: Cytogen Corporation; Food and Drug Administration ST: New Jersey IN: MTC SU:


MP -- PH002 -- 5492 07/01/92 08:32 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 1, 1992
Words:261
Previous Article:QUAL-MED PURCHASES 34-STATE INSURANCE COMPANY
Next Article:MARGARETTEN FINANCIAL IN NEGOTIATIONS TO PURCHASE A MAJOR MORTGAGE SERVICING PORTFOLIO FROM NATIONSBANK
Topics:


Related Articles
FDA ADVISORY COMMITTEE TO REVIEW CANCER IMAGING PRODUCT
CYTOGEN CORPORATION REPORTS ON DEVELOPMENTS CONNECTED WITH SEC FILING
CYTOGEN ANNOUNCES FDA ACCEPTANCE OF THE COMPANY'S FILING OF PROSTASCINT(TM) PRODUCT LICENSE APPLICATION
QUADRAMET(TM) NEW DRUG APPLICATION FILED BY FDA
CYTOGEN UPDATES STOCKHOLDERS ON RECENT BUSINESS DEVELOPMENTS AND THIRD QUARTER FINANCIAL RESULTS
CYTOGEN REPORTS BUSINESS UPDATE AND FIRST QUARTER RESULTS
/C O R R E C T I O N -- CYTOGEN/(Correction Notice)
CELLCOR TO MANUFACTURE NEOPROBE'S CELL THERAPY PRODUCT
Fletcher Asset Management Affiliate Invests $1.47 Million in CYTOGEN
CYTOGEN Corporation Issues Letter to Stockholders

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters